 According to the results of this phase I trial, both 5.0 × 1011 and 1.0 × 1012 virus particles VP of EDS01 showed adequate safety and treatment responses. Therefore, in the subsequent phase II clinical trial, the optimal of these two doses will be determined. The treatment effects and safety of this protocol for head and neck cancer will also be further investigated. 